A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells

A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells Molecular Therapy 24, 298 (February 2016). doi:10.1038/mt.2015.209 Authors: Kristina Nalivaiko, Martin Hofmann, Karina Kober, Nadine Teichweyde, Peter H Krammer, Hans-Georg Rammensee, Ludger Grosse-Hovest & Gundram Jung

http://feeds.nature.com/~r/mt/rss/current/~3/HS7zvGrPmgk/mt.2015.209

Source: Molecular Therapy - February 24, 2016 Category: Genetics & Stem Cells Authors: Kristina NalivaikoMartin HofmannKarina KoberNadine TeichweydePeter H KrammerHans-Georg RammenseeLudger Grosse-HovestGundram Jung Source Type: research

More News: Cancer & Oncology | Genetics